Cambrex opening new high-potency API facility in U.S.

Cambrex is set to open a new HPAPI facility at its Charles City, Iowa site. (Cambrex)

High-potency drugs remain in high demand, and Cambrex continues to build new facilities to capture that market. Its facility in Iowa will be ready to churn out active pharmaceutical ingredients beginning in May.

The East Rutherford, New Jersey-based small molecule specialist has completed a new $24 million facility in Charles City, Iowa. The 6,000-square-foot, four-reactor facility is currently being validated, the company said Wednesday.

With reactors that range from 200 to 1,000 gallons in capacity, the facility can handle projects up to 300 kg and support all phases of development, Cambrex said. A spokesman said in an email that Cambrex will add a dozen new jobs. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: Cambrex adds Avista Pharma to the fold in $250M deal

“We have seen an increased number of molecules in the clinical pipeline being designated as potent and highly potent, so having the flexibility within our manufacturing network to scale up with existing customers as projects progress, as well as accommodate new projects, is crucial to meet those market needs,” John Andrews, VP of operations and director for the Charles City site, said in a statement.

Cambrex manufactures a range of APIs and pharmaceutical intermediates including highly potent molecules and controlled substances at the Iowa site, where it employs more than 370 people.

Other companies are scaling up their high-potency API capabilities as well. A year ago, South Africa’s Aspen Pharmacare opened an $80 million facility at its site in Port Elizabeth.

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.